Benlysta (belimumab) - GSK
Lupkynis (voclosporin) - Aurinia Pharma, Otsuka
cyclosporin A microemulsion - Generic mfg.
Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis. (PubMed, Cells) - Oct 27, 2023 - "However, the traditional CNI, cyclosporine A and tacrolimus, have a narrow therapeutic range, need monitoring of drug levels, and their use is associated with nephrotoxicity and metabolic alterations...Here, we review the unique chemistry, pharmacology, and toxicity profile of VOC, summarize the efficacy and safety data from the AURA-LV and AURORA-1 trials, and discuss the following four possible options to implement VOC into the management of lupus nephritis, namely regarding B cell-targeting therapy with belimumab (BEL)...VOC-BEL sequential therapy, or 4. alternative options for the rapid antiproteinuric effect of VOC." 
Journal • Review • Cardiovascular • Glomerulonephritis • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
http://www.ncbi.nlm.nih.gov/pubmed/37887284
 
Ajinath Kale; Anil Bhanudas Gaikwad; Hans-Joachim Anders; Vishwadeep Shelke; Yutian Lei
 
Oct 27, 2023
 
Prev Next